Mass immunisation against poliomyelitis using principally oral live attenuated trivalent vaccine (OPV) has eradicated wild-type poliovirus transmission in the industrialised countries of the Western hemisphere and most other countries, and the global eradication of poliomyelitis is within reach. The risk of oral polio vaccine-associated poliomyelitis has been estimated by WHO at 0.5-3.4 cases per million of susceptible children, and by the Centers for Disease Control and Prevention (USA) at 1 case per 2.4 million doses of OPV. This has led to the reintroduction and use of inactivated vaccine in the USA and a number of other countries. The current risk of poliomyelitis for travellers is reviewed together with the application of strategies for immunisation against these infections.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.tmaid.2004.01.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enterovirus and Parechovirus Neurologic Infections in Children: Clinical Presentations and Neuropathogenesis.
J Pediatric Infect Dis Soc
January 2025
Sections of Hospital Medicine and Pediatric Infectious Diseases, University of Colorado, Aurora, CO, USA.
Enteroviruses (EVs) and parechoviruses (PeVs) are common pathogens of childhood. Enteroviral infections cause a range of clinical syndromes from mild illness to neurologic manifestations of meningitis, encephalitis, and acute flaccid myelitis. Disease manifestations are driven by a combination of viral replication and host immune response.
View Article and Find Full Text PDFBeyond Poliomyelitis: A 21-Year Study of Non-Polio Enterovirus Genotyping and Its Relevance in Acute Flaccid Paralysis in São Paulo, Brazil.
Viruses
December 2024
Divisão de Doenças de Transmissão Hídrica e Alimentar, Centro de Vigilância Epidemiológica "Prof. Alexandre Vranjac", Secretaria de Estado da Saúde de São Paulo, Sao Paulo 01246-900, Brazil.
In the context of the near-global eradication of wild poliovirus, the significance of non-polio enteroviruses (NPEVs) in causing acute flaccid paralysis (AFP) and their impact on public health has gained increased attention. This research, conducted from 2001 to 2021, examined stool samples from 1597 children under 15 years in São Paulo, Brazil, through the AFP/Poliomyelitis Surveillance Program, detecting NPEVs in 6.9% of cases.
View Article and Find Full Text PDFThe Glycopeptide PV-PS A1 Immunogen Elicits Both CD4+ and CD8+ Responses.
Vaccines (Basel)
December 2024
Department of Chemistry and Biochemistry and School of Green Chemistry and Engineering, University of Toledo, 2801 West Bancroft Street, Toledo, OH 43606, USA.
Background/objectives: The MHCII-dependent, CD4+ T-cell zwitterionic polysaccharide PS A1 has been investigated as a promising carrier for vaccine development because it can induce an MHCII-dependent CD4+ response towards a variety of tumor-associated carbohydrate antigens (TACAs). However, PS A1 cannot elicit cytotoxic T lymphocytes through MHCI, which may or may not hamper its potential clinical use in cancer, infectious and viral vaccine development. This paper addresses PS A1 MHCI independence through the introduction of an MHCI epitope, the poliovirus (PV) peptide, to establish an MHCI- and MHCII-dependent vaccine.
View Article and Find Full Text PDFSecuring the Future: Strategies for Global Polio Vaccine Security Amid Eradication Efforts.
Vaccines (Basel)
December 2024
World Health Organization, 1211 Geneva, Switzerland.
As we commemorate 50 years of the Expanded Programme on Immunization (EPI), the global mission to eradicate polio stands at a critical juncture. While remarkable progress has been made over the past decades, ensuring a steady supply of polio vaccines remains a significant challenge that could undermine these achievements. This manuscript aims to address the complexities of polio vaccine security within the context of the Immunization Agenda 2030 (IA2030) and the Global Polio Eradication Strategy 2022-2029, proposing actionable strategies to strengthen the vaccine supply.
View Article and Find Full Text PDFPolio Epidemiology: Strategies and Challenges for Polio Eradication Post the COVID-19 Pandemic.
Vaccines (Basel)
November 2024
Sanofi Vaccines Medical, 14 Espace Henri Vallee, 69007 Lyon, France.
The Global Polio Eradication Initiative (GPEI), launched in 1988, has successfully reduced wild poliovirus (WPV) cases by over 99.9%, with WPV type 2 and WPV3 declared eradicated in 2015 and 2019, respectively. However, as of 2024, WPV1 remains endemic in Afghanistan and Pakistan.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!